menu
    • menu
    [{"orgOrder":0,"company":"Evommune","sponsor":"AprilBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"EVO301","moa":"IL-18 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Evommune","highestDevelopmentStatusID":"6","companyTruncated":"Evommune \/ Evommune"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EVO301","moa":"IL-18 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EVO301","moa":"IL-18 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Evommune","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EVO101","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase I","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Evommune \/ Evommune","highestDevelopmentStatusID":"6","companyTruncated":"Evommune \/ Evommune"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EVO101","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EVO101","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EVO101","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Evommune","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Maruho","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Maruho"},{"orgOrder":0,"company":"Evommune","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Evommune","highestDevelopmentStatusID":"4","companyTruncated":"Evommune \/ Evommune"},{"orgOrder":0,"company":"Evommune","sponsor":"AccutarBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Evommune","highestDevelopmentStatusID":"3","companyTruncated":"Evommune \/ Evommune"},{"orgOrder":0,"company":"Evommune","sponsor":"Andera Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery","graph3":"Evommune","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Andera Partners","highestDevelopmentStatusID":"2","companyTruncated":"Evommune \/ Andera Partners"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"EVO756","moa":"MRGPRX2","graph1":"Immunology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"EVO756","moa":"MRGPRX2","graph1":"Immunology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Morgan Stanley"},{"orgOrder":0,"company":"Evommune","sponsor":"Morgan Stanley | Leerink Partners | Evercore ISI | Cantor","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"EVO756","moa":"MRGPRX2","graph1":"Immunology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Morgan Stanley | Leerink Partners | Evercore ISI | Cantor","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Morgan Stanley | Leerink Partners | Evercore ISI | Cantor"},{"orgOrder":0,"company":"Evommune","sponsor":"Morgan Stanley | Leerink Partners | Evercore ISI | Cantor","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"EVO756","moa":"MRGPRX2","graph1":"Immunology","graph2":"Phase II","graph3":"Evommune","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Morgan Stanley | Leerink Partners | Evercore ISI | Cantor","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Morgan Stanley | Leerink Partners | Evercore ISI | Cantor"},{"orgOrder":0,"company":"Evommune","sponsor":"Morgan Stanley | Leerink Partners | Evercore ISI | Cantor","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"EVO756","moa":"MRGPRX2","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.17000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Morgan Stanley | Leerink Partners | Evercore ISI | Cantor","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Morgan Stanley | Leerink Partners | Evercore ISI | Cantor"},{"orgOrder":0,"company":"Evommune","sponsor":"Morgan Stanley | Leerink Partners | Evercore ISI | Cantor","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"EVO756","moa":"MRGPRX2","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.17000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Morgan Stanley | Leerink Partners | Evercore ISI | Cantor","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Morgan Stanley | Leerink Partners | Evercore ISI | Cantor"}]

    Find Clinical Drug Pipeline Developments & Deals by Evommune

    Menu

    Evommune

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EVO756

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Morgan Stanley | Leerink Partners | Evercore ISI | Cantor

                            Deal Size : $172.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Evommune Closes IPO with Full Underwriters' Option Exercise

                            Details : In the public offering, EVO756, a miscellaneous product, will support the development of therapies targeting MRGPRX2 for chronic inflammatory diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 08, 2025

                            Lead Product(s) : EVO756

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Morgan Stanley | Leerink Partners | Evercore ISI | Cantor

                            Deal Size : $172.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EVO756

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Morgan Stanley | Leerink Partners | Evercore ISI | Cantor

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Evommune Enters IPO Class, Aims to Raise $160M for Immuno Pipeline

                            Details : The proceeds from the offering will be used to fund the clinical development of EVO756, a novel drug targeting MRGPRX2 for inflammatory conditions.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 05, 2025

                            Lead Product(s) : EVO756

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Morgan Stanley | Leerink Partners | Evercore ISI | Cantor

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EVO756

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Morgan Stanley | Leerink Partners | Evercore ISI | Cantor

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Evommune Sets Price for Initial Public Offering

                            Details : In the public offering, EVO756, a miscellaneous product, will support the development of therapies targeting MRGPRX2 for chronic inflammatory diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 05, 2025

                            Lead Product(s) : EVO756

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Morgan Stanley | Leerink Partners | Evercore ISI | Cantor

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EVO756

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Morgan Stanley | Leerink Partners | Evercore ISI | Cantor

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Evommune Begins Initial Public Offering

                            Details : The proceeds from the offering will be used to fund the clinical development of EVO756, a miscellaneous product targeting MRGPRX2 for chronic inflammatory diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 30, 2025

                            Lead Product(s) : EVO756

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Morgan Stanley | Leerink Partners | Evercore ISI | Cantor

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EVO756

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Inflammation Biotech Evommune Plans IPO for Dermatitis Trials Funding

                            Details : The proceeds from the offering will used to fund the clinical development of EVO756, a small molecule product, aims to address chronic spontaneous urticaria (CSU).

                            Product Name : EVO756

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 10, 2025

                            Lead Product(s) : EVO756

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EVO756

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Morgan Stanley

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Evommune Biotech Plans IPO for Dermatitis Trials Funding

                            Details : The net proceeds will fund the clinical development of EVO756, an oral small molecule antagonist of MRGPRX2

                            Product Name : EVO-756

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 10, 2025

                            Lead Product(s) : EVO756

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Morgan Stanley

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EVO756

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

                            Details : EVO756 is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 02, 2025

                            Lead Product(s) : EVO756

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EVO756

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evommune Starts Phase 2b Trial of EVO756 in Chronic Spontaneous Urticaria Patients

                            Details : EVO756 is a potent, highly selective small molecule antagonist of MRGPRX2. It is under clinical development for the treatment of chronic spontaneous urticaria.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 15, 2025

                            Lead Product(s) : EVO756

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EVO301

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evommune Starts Phase 2 Trial of IL-18 Fusion Protein EVO301 for Atopic Dermatitis

                            Details : EVO301 is a serum albumin Fab-associated IL-18BP fusion protein, which is currently being evaluated for the treatment of adult patients with moderate-to-severe atopic dermatitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 17, 2025

                            Lead Product(s) : EVO301

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Evommune

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EVO756

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

                            Details : EVO756 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chronic Urticaria.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2025

                            Lead Product(s) : EVO756

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth